Innate immune responses of synthetic lipid A derivatives of Neisseria meningitidis.
Differences in the pattern and chemical nature of fatty acids of lipid A of Neisseria meningitides lipooligosaccharides (LOS) and Escherichia coli lipopolysaccharides (LPS) may account for differences in inflammatory properties. Furthermore, there are indications that dimeric 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) moieties of LOS and LPS enhance biological activities. Heterogeneity in the structure of lipid A and possible contaminations with other inflammatory components have made it difficult to confirm these observations. To address these problems, a highly convergent approach for the synthesis of a lipid A derivative containing KDO has been developed, which relies on the ability to selectively remove or unmask in a sequential manner an isopropylidene acetal, 9-fluorenylmethoxycarbonyl (Fmoc), allyloxycarbonate (Alloc), azide, and thexyldimethylsilyl (TDS) ether. The strategy was employed for the synthesis of N. meningitidis lipid A containing KDO (3). Mouse macrophages were exposed to the synthetic compound and its parent LOS, E. coli lipid A (2), and a hybrid derivative (4) that has the asymmetrical acylation pattern of E. coli lipid A, but the shorter lipids of meningococcal lipid A. The resulting supernatants were examined for tumor necrosis factor alpha (TNF-alpha) and interferon beta (IFN-beta) production. The lipid A derivative containing KDO was much more active than lipid A alone and just slightly less active than its parent LOS, indicating that one KDO moiety is sufficient for full activity of TNF-alpha and IFN-beta induction. The lipid A of N. meningitidis was a significantly more potent inducer of TNF-alpha and IFN-beta than E. coli lipid A, which is due to a number of shorter fatty acids. The compounds did not demonstrate a bias towards a MyD88- or TRIF-dependent response.
Zhang
Yanghui
Y
Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, GA 30602, USA.
Gaekwad
Jidnyasa
J
Wolfert
Margreet A
MA
Boons
Geert-Jan
GJ
D000818:Animals; D002236:Carbohydrate Conformation; D004926:Escherichia coli / Q000737:chemistry / Q000276:immunology; D007113:Immunity, Innate / Q000187:drug effects; D007159:Immunologic Tests; D016899:Interferon-beta / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D008050:Lipid A / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000737:chemistry / Q000494:pharmacology; D008264:Macrophages / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D015394:Molecular Structure; D009345:Neisseria meningitidis / Q000737:chemistry* / Q000276:immunology; D013237:Stereoisomerism; D013400:Sugar Acids / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology
D008050:Lipid A; D008070:Lipopolysaccharides; D013400:Sugar Acids; D014409:Tumor Necrosis Factor-alpha; C023023:lipid-linked oligosaccharides; C002532:2-keto-3-deoxyoctonate; D016899:Interferon-beta